Chimeric antigen receptor-T cells (CAR-T) based on circRNA encoding the anti-Delta-like Ligand 3 (DLL3) show enhanced efficacy toward small cell lung cancer (SCLC) compared to CAR-T cells based on mRNA [176]. This evidence concerns the gene DLL3 and small cell lung carcinoma.